24/04/2017
Auris Medical Reports Key Results from Keyzilen® AMPACT2 Open-Label Extension Study
Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced key results from AMPACT2 (AM-101 in thePost-Acute Treatment [...]
